Development Agreement With Nurron Pharmaceuticals To Develop Therapy For Parkinson's Disease
25/05/2023 12:43
May 25 (Reuters) - Hanall Biopharma Co Ltd 009420.KS :
* HANALL BIOPHARMA AND DAEWOONG PHARMACEUTICAL ENTER INTO
CO-DEVELOPMENT AGREEMENT WITH NURRON PHARMACEUTICALS TO DEVELOP
THERAPY FOR PARKINSON'S DISEASE
* HANALL BIOPHARMA CO LTD- HANALL BIOPHARMA AND DAEWOONG
PHARMACEUTICAL WILL CO-DEVELOP NURRON PHARMACEUTICALS' NOVEL
INVESTIGATIONAL COMPOUNDS
* HANALL BIOPHARMA CO LTD- PHASE 1 CLINICAL TRIAL IS
EXPECTED TO
BE INITIATED IN 2023
* HANALL BIOPHARMA CO LTD- CO, DAEWOONG PHARMACEUTICAL WILL
CONTINUE TO EXPLORE POTENTIAL OF ATH-399A IN OTHER
NEURODEGENERATIVE DISEASES
Source text for Eikon: ID:nPn2zPVZDa
Further company coverage: 009420.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hanall Biopharma
See all newsQ2 2026 Operating Profit Up 567.4% QoQ, 388.5% YoY To Won 5.60 Billion
Brief: Hanall Biopharma Co Icc Rules Licensing Deal With Harbour Biomed Continues To Be Effective
Brief: Hanall Biopharma Q1 Operating Profit 839 Million Won, Swings To Profit From Year Earlier
Immunovant falls as drug for thyroid eye disease fails late-stage trials
Immunovant falls as eye disease therapy fails in late-stage studies